Leadership Team

Mr. Pauls has served as President, Chief Executive Officer, and director since 2010 and was Chairman of the board from 2008 to 2014. Mr. Pauls was previously the co-founder and Managing Director of CentreStone Ventures Inc., a life sciences venture capital fund. Prior to CentreStone, he was with Centara Corporation, another early stage venture capital fund. Before this, Mr. Pauls specialized in asset-backed securitization and structured finance at the General Motors Acceptance Corporation in Minnesota.  He received his Bachelor of Arts in Economics from the University of Manitoba and his M.B.A. in Finance from the University of North Dakota.

Dr. Verdoorn has more than 26 years of experience working with both public and private pharmaceutical and biotechnology companies to develop new treatments for neurological diseases, including five years working with Bristol-Myers Squibb's stroke group and as the former Chief Scientific Officer for several private life sciences companies. Dr. Verdoorn earned his PhD in Neurobiology from the University of North Carolina, conducting his post-doctoral research at the Max Planck Institute with Nobel Laureate Dr. Bert Sakmann, served as Associate Professor of Pharmacology at Vanderbilt University School of Medicine and is the author of numerous publications and patents. Dr. Verdoorn was formerly Vice President of Neuroscience with DiaMedica.

Dr. Alcorn has over 30 years of clinical research experience working with public and private biotech and pharmaceutical companies in studies of kidney diseases and diabetic, hepatic and cardiovascular patients. He has designed, authored and been a consultant to a multitude of companies in the industry on protocol development, clinical execution and regulatory guidance. He has served as Principal Investigator or Sub Investigator in over 450 clinical studies and has assisted many biotech and pharmaceutical companies in negotiating protocols and presenting results to the FDA. Dr. Alcorn has presented at numerous international meetings and industry seminars discussing the critical challenges in conducting patient studies.

Prior to joining DiaMedica, Dr. Alcorn served as Chief Scientific Officer at DaVita Clinical Research (DaVita), a company that provides clinical research services for pharmaceutical and biotech companies. During this time, he also served on the Board of Directors for The Association of Clinical Pharmacology Units and on the Board of Directors of MedTox Laboratories. In 2000 Dr. Alcorn started the US Renal Network, the first organization to coordinate clinical trial sites for the conduct of kidney studies. Prior to DaVita he held the position of Executive Director and led the clinical trials at GalaGen Inc, a biopharmaceutical company developing therapeutics to target life-threatening and emerging pathogens.

Dr. Alcorn obtained his Bachelor of Pharmacy from Creighton University and his Doctor of Pharmacy from University of Nebraska Medical Center. He currently holds clinical faculty appointments with the University of Minnesota, Creighton University, University of Nebraska Medical Center, Virginia Commonwealth and the University of Colorado, Denver.

Mr. Kellen is a highly qualified senior executive with corporate board experience. He has held positions as Chief Operating Officer and Chief Financial Officer within publicly traded healthcare companies, most recently as CFO for Sun Bio Pharma. In addition to the positions he has played, Mr. Kellen has significant experience with capital formation, public company reporting and corporate governance.

Mr. Kellen has held a Certified Public Accountant certificate, and graduated summa cum laude from the University of South Dakota with a Bachelor of Science in Business Administration.

Mr. Papi has extensive experience as an entrepreneurial senior executive with 38 years of demonstrated success in life sciences, investment banking, general management, product and business development, and sales and marketing leadership. Mr. Papi spent 28 years as an executive for Mylan Laboratories, providing the basis of his life science experience. His work at Mylan, as well as experience with young life science companies, provides him a unique perspective in understanding the rigors of getting through the FDA and balancing the cash flow requirements for funding the clinical process. Mr. Papi previously held a Series 7, Series 63 license and specialized in institutional equity raises, corporate development, and mergers and acquisitions. He has been a moderator at life science conferences for fund raising and has a superior track record helping young companies with strategy, financing, outreach, business expansion, networking, and communication skills.